### Systemic Therapy as Primary or Adjuvant Therapy

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Limited Stage (maximum of 4–6 cycles)</strong>&lt;sup&gt;a,c&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>Preferred Regimens</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Cisplatin + Etoposide<sup>3,4</sup> | Day 1: Cisplatin 60mg/m² IV over 60 minutes  
Days 1–3: Etoposide 120mg/m² IV over 60 minutes.  
Repeat cycle every 3-4 weeks for 4-6 cycles.  
OR  
Day 1: Cisplatin 75mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes.  
Repeat cycle every 3-4 weeks for 4–6 cycles |
| **Other Recommended Regimens** | |
| Carboplatin + Etoposide<sup>5,6,4</sup> | Day 1: Carboplatin AUC 5–6 IV over 30 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes.  
Repeat cycle every 3-4 weeks for 4–6 cycles. |
| Cisplatin + Etoposide<sup>3,6</sup> | Days 1–3: Cisplatin 25mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes.  
Repeat cycle every 3-4 weeks for 4–6 cycles. |
| **Extensive Stage SCLC (maximum of 4-6 cycles)**<sup>i</sup> | |
| **Preferred Regimens** | |
| Carboplatin + Etoposide + Atezolizumab (Category 1)<sup>10,11</sup> | Day 1: Carboplatin AUC 5 IV over 30 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes  
Day 1: Atezolizumab 1,200mg IV.  
Repeat cycle every 3 weeks for 4 cycles.  
Day 1: Atezolizumab 1,200mg IV.  
Repeat cycle every 3 weeks. |
| Carboplatin + Etoposide + Durvalumab (Category 1)<sup>11,12</sup> | Day 1: Carboplatin AUC 5-6 IV over 30 minutes  
Days 1–3: Etoposide 80-100mg/m² IV over 60 minutes  
Day 1: Durvalumab 1,500mg IV over 60 minutes  
Repeat cycle every 3 weeks for 4 cycles, followed by maintenance therapy with:  
Day 1: Durvalumab 1,500mg IV over 60 minutes.  
Repeat cycle every 4 weeks. |
| Cisplatin + Etoposide + Durvalumab (Category 1)<sup>11,12</sup> | Day 1: Cisplatin 75-80mg/m² IV over 120 minutes  
Days 1–3: Etoposide 80-100mg/m² IV over 60 minutes  
Day 1: Durvalumab 1,500mg IV over 60 minutes  
Repeat cycle every 3 weeks for 4 cycles, followed by maintenance therapy with:  
Day 1: Durvalumab 1,500mg IV over 60 minutes.  
Repeat cycle every 4 weeks. |
| **Other Recommended Regimens** | |
| Carboplatin + Etoposide<sup>5,8</sup> | Day 1: Carboplatin AUC 5–6 IV over 30 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes.  
Repeat cycle every 3-4 weeks for 4–6 cycles. |

Note: All recommendations are Category 2A unless otherwise indicated.
Small Cell Lung Cancer Treatment Regimens

Systemic Therapy as Primary or Adjuvant Therapy

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary or Adjuvant Therapy for Extensive Stage SCLC (maximum of 4-6 cycles)</strong></td>
<td></td>
</tr>
</tbody>
</table>

Other Recommended Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Cisplatin + Etoposide | Day 1: Cisplatin 75mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles.  
OR  
Day 1: Cisplatin 80mg/m² IV over 60 minutes  
Days 1–3: Etoposide 80mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles.  
OR  
Days 1–3: Cisplatin 25mg/m² IV over 60 minutes  
Days 1–3: Etoposide 100mg/m² IV over 60 minutes. Repeat cycle every 3-4 weeks for 4–6 cycles. |

Useful in Certain Circumstances

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Carboplatin + Irinotecan | Day 1: Carboplatin AUC 5 IV over 30 minutes  
Days 1, 8, and 15: Irinotecan 50mg/m² IV over 90 minutes. Repeat cycle every 4 weeks for 4–6 cycles. |

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Cisplatin + Irinotecan | Day 1: Cisplatin 60mg/m² IV over 60 minutes  
Days 1, 8, and 15: Irinotecan 60mg/m² IV over 90 minutes. Repeat cycle every 4 weeks for 4 cycles.  
OR  
Day 1 and 8: Cisplatin 30mg/m² IV over 60 minutes  
Day 1 and 8: Irinotecan 65mg/m² IV over 90 minutes. Repeat cycle every 3 weeks for 4–6 cycles. |

Subsequent Systemic Therapy

Relapse ≤6 months, PS 0-2

Preferred Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lurbinectedin</td>
<td>Day 1: Lurbinectedin 3.2 mg/m² IV over 60 minutes. Repeat cycle every 3 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Topotecan | Days 1–5: Topotecan 1.5mg/m² IV daily over 30 minutes. Repeat cycle every 3 weeks.  
OR  
Days 1–5: Topotecan 2.3mg/m² orally once daily. Repeat cycle every 3 weeks. |

Other Recommended Regimens

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bendamustine (Category 2B)</td>
<td>Days 1 and 2: Bendamustine 120mg/m² IV over 10 minutes or 60 minutes (based on product selection). Repeat cycle every 3 weeks for 6 cycles.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
</table>
| Cyclophosphamide + Doxorubicin + Vincristine (CAV) | Day 1: Cyclophosphamide 1,000mg/m² IV over 60 minutes  
Day 1: Doxorubicin 45mg/m² IV push  
Day 1: Vincristine 2mg IV over 5-10 minutes. Repeat cycle every 3 weeks. |

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Docetaxel</td>
<td>Day 1: Docetaxel 60-100 mg/m² IV over 60 minutes. Repeat cycle every 3 weeks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemcitabine</td>
<td>Days 1, 8, and 15: Gemcitabine 1,000mg/m² IV over 30 minutes. Repeat cycle every 4 weeks.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REGIMEN</th>
<th>DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irinotecan</td>
<td>Days 1,8,15,22: Irinotecan 100mg/m² IV over 90 minutes. Repeat cycle every 4 weeks.</td>
</tr>
</tbody>
</table>

continued
## Subsequent Systemic Therapy\(^{1,\text{g}}\)

<table>
<thead>
<tr>
<th>Relapse ≤6 months, PS 0-2</th>
<th>Other Recommended Regimens</th>
</tr>
</thead>
</table>
| **Nivolumab\(^{28-30,a,f}\)** | **Day 1:** Nivolumab 240mg IV over 30 minutes  
Repeat cycle every 2 weeks.  
**OR**  
**Day 1:** Nivolumab 480mg IV over 30 minutes  
Repeat cycle every 4 weeks. |
| **Nivolumab + Ipiilimumab\(^{28-31,a,f}\)** | **Day 1:** Nivolumab 1mg/kg IV over 30 minutes  
**Day 1:** Ipiilimumab 3mg/kg IV over 90 minutes  
Repeat cycle every 3 weeks for 4 cycles, **followed by:**  
**Day 1:** Nivolumab 240mg IV over 30 minutes.  
Repeat cycle every 2 weeks.  
**OR**  
**Day 1:** Nivolumab 1mg/kg IV over 30 minutes  
**Day 1:** Ipiilimumab 3mg/kg IV over 90 minutes  
Repeat cycle every 3 weeks for 4 cycles, **followed by:**  
**Day 1:** Nivolumab 480mg IV over 30 minutes.  
Repeat cycle every 4 weeks. |
| **Oral Etoposide\(^{35,36}\)** | **Days 1–21:** Etoposide 50mg/m\(^2\) orally once daily.  
Repeat cycle every 4 weeks. |
| **Paclitaxel\(^{34,35}\)** | **Day 1:** Paclitaxel 175mg/m\(^2\) IV over 3 hours.  
Repeat cycle every 3 weeks.  
**OR**  
**Days 1,8,15,22,29,36:** Paclitaxel 80mg/m\(^2\) IV over 60 minutes.  
Repeat cycle every 8 weeks (6 weeks on followed by 2 weeks off). |
| **Pembrolizumab\(^{36-38,a,f}\)** | **Day 1:** Pembrolizumab 200mg IV over 30 minutes.  
Repeat cycle every 3 weeks. |
| **Temozolomide\(^{39,40}\)** | **Days 1–21:** Temozolomide 75mg/m\(^2\) orally once daily.  
Repeat cycle every 4 weeks.  
**OR**  
**Days 1–5:** Temozolomide 200mg/m\(^2\) orally once daily.  
Repeat cycle every 4 weeks. |
| **Vinorelbine\(^{41,42}\)** | **Days 1, 8, 15:** Vinorelbine 25–30mg/m\(^2\) IV over 5–10 minutes.  
Repeat cycle every 3 weeks. |

### Relapse >6 months\(^1\)

**Preferred**

**Original regimen\(^{16}\)**

**Other Recommended Regimen**

| Lurbinectin\(^{19}\) | **Day 1:** Lurbinectedin 3.2mg/m\(^2\) IV over 60 minutes.  
Repeat cycle every 3 weeks |

---

\(^a\) Planned cycle length should be every 21–28 days during concurrent RT.

\(^b\) During systemic therapy + radiotherapy, cisplatin/etoposide is recommended (category 1).

\(^c\) The use of myeloid growth factors is not recommended during concurrent systemic therapy plus radiotherapy (category 1 for not using GM-CSF).\(^7\)

\(^d\) Cisplatin contraindicated or not tolerated.

\(^e\) Regimen is not recommended for relapsed disease in patients on maintenance atezolizumab at time of relapse. For patients who relapse after >6 months of atezolizumab in maintenance therapy, recommend re-treatment with carboplatin + etoposide alone.

\(^f\) Contraindications for treatment of PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or concurrent use of immunosuppressive agents.

\(^g\) Subsequent systemic therapy refers to second-line and beyond therapy.
Small Cell Lung Cancer Treatment Regimens

References


